Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will be hosting a webinar to provide an overview of how LINZESS will be reflected in Ironwood’s quarterly income statements following its commercial availability in the U.S. Ironwood will co-commercialize the product in the U.S. through its collaboration with Forest Laboratories, Inc.
The webinar will take place on Tuesday, November 6, 2012 at 12:00 p.m. Eastern Time. Individuals interested in participating in the webinar should visit the Investors section of Ironwood’s website at www.ironwoodpharma.com; please log on at least 15 minutes prior to the start of the event to ensure adequate time for any software downloads that may be required. For listen-only participation, the webinar can also be accessed by dialing (866) 437-1772 (U.S. and Canada) or (973) 638-3229 (international) and use the conference ID number 45259150.
A replay of the webinar will be available on Ironwood’s website or via telephone starting November 6, 2012 at approximately 3:00 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on November 13, 2012. To listen to the replay by phone, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) and use conference ID number 45259150.
About Ironwood PharmaceuticalsIronwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV